Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

28 Aug 2013
by Working Group

Posted in Announcements, Events, TB Drug Development

6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs September 9, 2013 in Denver, CO.

tb-e1332174457196

This interactive workshop is held in conjunction with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  The workshop is intended to provide clinicians, researchers, students and representatives from regulatory non-government organizations active in the TB-field with a platform for presentation and discussion of the latest scientific developments in the field.  The workshop will allow [...]

30 Jul 2013

EMA fails to recommend Otsuka’s Delamanid for MDR TB

otsuka

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) failed to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB). A letter from the Treatment Action Group criticizing this decision is included.

17 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Sequella Acquires Exclusive Worldwide Rights to Pfizer’s Sutezolid

PNU100480

Sequella today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).

10 Jul 2013
by Working Group

Posted in Faces of TB, TB Drug Development, TB News

How to Combat Tuberculosis: NPR Highlights

npr

Yesterday, the US National Public Radio posted online two insightful pieces on tuberculosis: 1) What It Takes To Cure Drug-Resistant Tuberculosis 2) Treating The ‘Body And Soul’ In A Russian TB Prison

9 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Otsuka Begins Paediatric MDR-TB Trials

otsuka

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

1 Jul 2013
by Working Group

Posted in Action, TB Drug Development, TB News

TAG Releases 2013 Pipeline Report

Click here to access full report

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

24 Jun 2013
by Working Group

Posted in Announcements, Early Drug Development, Events

“Targets for Tomorrow” Workshop at GRC in Italy July 2013

tb-review-4.10-lipsitch-feature

We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy.

13 Jun 2013

WHO Issues Interim Guidance on the Use of Bedaquiline to Treat

who-logo

The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB).

TB R&D Update: Vitamin C Kills Tuberculosis in vitro

ncomms2898-i1

This week we highlight a study out of Dr. William Jacobs, Jr.’s lab showing that “vitamin C, a compound known to drive the Fenton reaction, sterilizes cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis.” Additional links to other news and articles related to TB R&D are included.

UPDATE Exposed: Aeras’ Film Series on Tuberculosis

exposed

Release of Chapter 1 of EXPOSED occured the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals – an MDR-TB survivor, a TB doctor, a clinical trial volunteer, and a TB vaccine researcher – bringing viewers to the forefront of the race against tuberculosis. Click article to view the trailer and Chapter 1 “The Global Epidemic”.